Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492443 | 1.00 | CYP2D6 (0.43) | CYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL7063746 | 0.84 | CYP2D6 (0.48) | CYP2D6 | |
| SCHEMBL11092615 | 0.83 | GABRR1 (0.32) | — | |
| SCHEMBL3093921 | 0.81 | CYP2D6 (0.41) | CYP2D6 | |
| SCHEMBL5878869 | 0.77 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL283340 | 0.77 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL283339 | 0.77 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL2245340 | 0.77 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL3066938 | 0.76 | — | — | |
| SCHEMBL24192869 | 0.75 | CYP2D6 (0.43) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154937-B1 | CHLORINE-RESISTANT POLYETHYLENE COMPOUND AND ARTICLES MADE THEREFROM | FINA TECHNOLOGY (US) | 2024-05-22 | — | — | EP | claimed |
| US-4217237-A | Process for removing carbon dioxide containing acidic gases from gaseous mixtures using a basic salt activated with a hindered amine | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-08-12 | — | — | US | claimed |
| EP-3154937-B1 | CHLORINE-RESISTANT POLYETHYLENE COMPOUND AND ARTICLES MADE THEREFROM | FINA TECHNOLOGY (US) | 2024-05-22 | — | — | EP | disclosed |
| US-8586552-B2 | 4,6-substituted 2,5-dideoxystreptamine aminoglycoside antibiotics | SELECTX PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130203693-A1 | 4,6-SUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS | SELECTX PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-7927581-B2 | For magnetic resonance imaging (MRI); peptide modified at its N- and its C-termini, independently, with a moiety comprising a metal chelate complex; specific binding affinity for fibrin; sufficient half-life in vivo | Factor 1A, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7238341-B2 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | CYP2D6 4872/4885ADRB2 3841/4885ADRB1 3838/4885 |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | NGLY1, IAPP, NPPA | CYP2D6 4872/4885ADRB2 3841/4885ADRB1 3838/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | CYP2D6 4872/4885ADRB2 3841/4885ADRB1 3838/4885 |
| US-20130203693-A1 | 4,6-SUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS | SLC11A2, MRPL21, GNPAT | CYP2D6 48/4885ADRB2 510/4885ADRB1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.